Virtual Library
Start Your Search
T. Shiraishi
Author of
-
+
P1.08 - Poster Session with Presenters Present (ID 460)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.08-072 - The Result of Completion Pneumonectomy for the Local Recurrent Lung Cancer after Radical Lobectomy (ID 4522)
14:30 - 14:30 | Author(s): T. Shiraishi
- Abstract
Background:
Retrospective review on the result of completion pneumonectomy (CP) for the local recurrent non-small cell lung cancer (NSCLC) following the radical lobectomy, performed by a single institution.
Methods:
From 1995 to 2015, 12 consecutive patients underwent CP for cure of loco-regional recurrent NSCLC. Eleven out of these were the cases with recurrent tumor at resection margin of previous surgery and the rest was the case with multiple metastatic tumors within the ipsilateral remaining lung lobe. The right CP was performed for 5 patients (41.6%) and the left for 7 (58.3%).
Results:
Operative mortality was 0% and major complications occurred to 3 patients (25%). The operations were performed by the posterolateral thoracotomy for 7 patients, and 5 by the anterior approaches (median sternotomy or hemi-clamshell thoracotomy). The control of hilar components was achieved through an intra-pericardial route in all cases. In two cases, the infiltration of the recurrent tumors were confirmed in the carinal bifurcation. Thus, the completion “sleeve” pneumonectomy was performed. The complete resections were achieved in all patients. Mean observation period was 1313 days after CP at the time of this investigation. Four patients deceased including 2 cancer re-relapse death and 2 cancer unrelated death. There are 8 survivors for more than one year after CP including 4 patients surviving without cancer relapse (mean survival time [MST] of 1214 days) and 4 surviving with either local or distant cancer relapse (MST = 1354 days). Among those 4 survivors with cancer relapse, 3 patients were treated with molecular targeted drugs after gene-mutation survey for susceptibility of specific molecular targeted drugs using tumor specimen harvested from CP surgery. Another patient with cancer relapse was found to be unsuitable for any type of molecular targeted drugs, thus treated with cisplatin based conventional anti-cancer protocol. Five year survival rate for the entire series was 66.7%.
Conclusion:
Completion pneumonectomy has been considered as a complex and high risk surgical procedure, however, due to the recent progresses made in the surgical techniques and post-operative management, the CP in the setting of locally recurrent NSCLC became safe and favorable treatment option. More importantly, tumor specimen obtained by the CP can be used for selecting the updated molecular target drugs which might be helpful for patient’s long term survival.
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-035 - Can Airway Stenting Avoid Suffocation Deaths Caused by Malignant Airway Obstruction? (ID 4241)
14:30 - 14:30 | Author(s): T. Shiraishi
- Abstract
Background:
Airway stenting is undoubtedly the mainstay procedure for treating patients with malignant airway stenosis to prevent a variety of airway symptoms. Suffocation death is the most painful ending for those patients. The impact of airway stent treatment to avoid this tragic event was investigated.
Methods:
Between 2000 and 2014, 57 patients underwent airway stenting in our department for malignant airway stenosis. They included 25 lung cancer cases, 15 esophageal cancer cases and 7 thyroid cancer cases. The location of the stenosis was the carina for 31 cases, the right or left main bronchus in 12, and the trachea 14. Either Dumon silicon (n=50) or self-expandable metallic stents (n=7) were used. The effect of airway stenting to prevent suffocation death, and the factors for predicting the prognosis were analyzed.
Results:
There were no cases of in-hospital death. An improvement in airway symptoms was achieved in 54 patients (94.7%) and the median survival after stenting was 3.7 months. At death, only 8 (14%) of those patients died due to direct airway symptoms, including respiration difficulty, even when their general condition was good (Suffocation death group). Conversely, the other 49 patients mostly died due to systemic cancer spread, but all 49 cases had no pain associated with airway symptoms. Therefore, suffocation death appears to have been avoided in those 49 (85.9%) patients (Non-suffocation death group). In a univariate analysis, “Stent migration”, “Tracheal stenosis”, and “Thyroid cancer” were potentially significant factors regarding suffocation death. In a multivariate analysis, “Stenosis at mid trachea” was found to be an independent predictive factor for suffocation death (p = 0.02).
Conclusion:
Suffocation death can be effectively prevented by the use of airway stenting treatment. “Stenosis at mid trachea” is the most problematic factor when attempting to obtain some benefit from stenting and this may be due to the difficulty of achieving accurate stent (mainly straight silicon stent) fixation in such lesions.
